Restriction of interleukin‐6 alters endothelial cell immunogenicity in an allogenic environment. Issue 12 (14th November 2022)

• Record Type: Journal Article
• Authors: Lion, Julien; Maitre, Mathilde Le; de Truchis, Camille; Taupin, Jean‐Luc; Poussin, Karine; Haziot, Alain; Chong, Edward; Glotz, Denis; Mooney, Nuala
• Is Part Of: Clinical transplantation. Volume 36:Issue 12(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-11-14
• Subjects: alloantibodies -- complement -- donor specific antibodies -- endothelium -- HLA; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ctr.14815
• Languages: English
• ISSNs: 0902-0063

Abstract

Abstract: The microvascular endothelium of the renal transplant is the first site of graft interaction with the host immune system and is often injured in chronic Antibody Mediated Rejection (AMR). Microvascular inflammation is an independent determinant of AMR and heightens endothelial expression of human leukocyte antigen (HLA) molecules thereby increasing the possibility of Donor Specific Antibody (DSA) binding. Endothelial cells (ECs) produce IL‐6 in the steady‐state that is increased by inflammation or by HLA‐DR antibody binding in an allogeneic setting. Because IL‐6 has been implicated in AMR, IL‐6 blockade is currently under investigation as a therapeutic target. To further understand the role of IL‐6 in EC immunogenicity, we have examined whether humanized antibody blockade of IL‐6 altered EC interactions with allogeneic PBMC and after anti‐HLA or DSA binding to ECs in an in vitro human experimental model. Soluble factors, endothelial phenotype, Stat‐3 activation, CD4 + ‐T differentiation and C4d deposition were examined. Blockade of IL‐6 reduced EC secretion of IL‐6 and of the monocyte chemoattractant MCP‐1. Pre‐activation of ECs by anti‐HLA or DSA binding increased IL‐6 secretion, that was further increased by concurrent binding of both antibodies and this was inhibited by IL‐6 blockade. Activation of Stat‐3 in CD4 + ‐T mediated by soluble factors produced in endothelial‐PBMC interactions, and endothelial differentiation of CD4 + ‐T cell subsets (Th1, Treg), were impaired whereas activation of Complement by anti‐HLA antibody binding remained unchanged by IL‐6 blockade. Together, these data identify EC‐mediated pro‐inflammatory responses (T cell expansion, EC auto‐activation, chemokine secretion) targeted by IL‐6 blockade.